373 related articles for article (PubMed ID: 35883598)
1. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.
McCubrey JA; Yang LV; Abrams SL; Steelman LS; Follo MY; Cocco L; Ratti S; Martelli AM; Augello G; Cervello M
Cells; 2022 Jul; 11(14):. PubMed ID: 35883598
[TBL] [Abstract][Full Text] [Related]
2. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.
McCubrey JA; Meher AK; Akula SM; Abrams SL; Steelman LS; LaHair MM; Franklin RA; Martelli AM; Ratti S; Cocco L; Barbaro F; Duda P; Gizak A
Aging (Albany NY); 2022 Apr; 14(8):3365-3386. PubMed ID: 35477123
[TBL] [Abstract][Full Text] [Related]
3. Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53.
Abrams SL; Duda P; Akula SM; Steelman LS; Follo ML; Cocco L; Ratti S; Martelli AM; Montalto G; Emma MR; Cervello M; Rakus D; Gizak A; McCubrey JA
Cells; 2022 Feb; 11(5):. PubMed ID: 35269416
[TBL] [Abstract][Full Text] [Related]
4. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
Sun H; Zhang B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
[TBL] [Abstract][Full Text] [Related]
5. MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus.
Godfrey JD; Morton JP; Wilczynska A; Sansom OJ; Bushell MD
Cell Death Dis; 2018 May; 9(6):644. PubMed ID: 29844410
[TBL] [Abstract][Full Text] [Related]
6.
Maddalena M; Mallel G; Nataraj NB; Shreberk-Shaked M; Hassin O; Mukherjee S; Arandkar S; Rotkopf R; Kapsack A; Lambiase G; Pellegrino B; Ben-Isaac E; Golani O; Addadi Y; Hajaj E; Eilam R; Straussman R; Yarden Y; Lotem M; Oren M
Proc Natl Acad Sci U S A; 2021 Jun; 118(23):. PubMed ID: 34088837
[TBL] [Abstract][Full Text] [Related]
7. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals.
Candido S; Abrams SL; Steelman LS; Lertpiriyapong K; Martelli AM; Cocco L; Ratti S; Follo MY; Murata RM; Rosalen PL; Bueno-Silva B; de Alencar SM; Lombardi P; Mao W; Montalto G; Cervello M; Rakus D; Gizak A; Lin HL; Libra M; Akula SM; McCubrey JA
Adv Biol Regul; 2019 May; 72():22-40. PubMed ID: 30898612
[TBL] [Abstract][Full Text] [Related]
8. APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells.
McCubrey JA; Abrams SL; Steelman LS; Cocco L; Ratti S; Martelli AM; Lombardi P; Gizak A; Duda P
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204775
[TBL] [Abstract][Full Text] [Related]
9. Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.
Datta J; Bianchi A; De Castro Silva I; Deshpande NU; Cao LL; Mehra S; Singh S; Rafie C; Sun X; Chen X; Dai X; Colaprico A; Sharma P; Dosch AR; Pillai A; Hosein PJ; Nagathihalli NS; Komanduri KV; Wilson JM; Ban Y; Merchant NB
Oncogene; 2022 Jul; 41(28):3640-3654. PubMed ID: 35701533
[TBL] [Abstract][Full Text] [Related]
10. Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies.
McCubrey JA; Abrams SL; Follo MY; Manzoli L; Ratti S; Martelli AM; Cervello M
Adv Biol Regul; 2023 Jan; 87():100917. PubMed ID: 36243652
[TBL] [Abstract][Full Text] [Related]
11. TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma.
Zhou Y; Jin J; Ji Y; Zhang J; Fu N; Chen M; Wang J; Qin K; Jiang Y; Cheng D; Deng X; Shen B
J Transl Med; 2023 Dec; 21(1):872. PubMed ID: 38037073
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53.
Abrams SL; Akula SM; Martelli AM; Cocco L; Ratti S; Libra M; Candido S; Montalto G; Cervello M; Gizak A; Rakus D; Steelman LS; McCubrey JA
Adv Biol Regul; 2021 Jan; 79():100780. PubMed ID: 33451973
[TBL] [Abstract][Full Text] [Related]
13. TP53/miR-34a-associated signaling targets
Akula SM; Ruvolo PP; McCubrey JA
Aging (Albany NY); 2020 Jan; 12(3):2777-2797. PubMed ID: 31986125
[TBL] [Abstract][Full Text] [Related]
14. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
15. Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53.
Abrams SL; Akula SM; Steelman LS; Follo ML; Cocco L; Ratti S; Martelli AM; Libra M; Falzone L; Candido S; Montalto G; Cervello M; Lombardi P; McCubrey JA
Adv Biol Regul; 2022 Jan; 83():100840. PubMed ID: 34866036
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
17. ARF6 and AMAP1 are major targets of
Hashimoto S; Furukawa S; Hashimoto A; Tsutaho A; Fukao A; Sakamura Y; Parajuli G; Onodera Y; Otsuka Y; Handa H; Oikawa T; Hata S; Nishikawa Y; Mizukami Y; Kodama Y; Murakami M; Fujiwara T; Hirano S; Sabe H
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17450-17459. PubMed ID: 31399545
[TBL] [Abstract][Full Text] [Related]
18. Small-Molecule MMRi62 Induces Ferroptosis and Inhibits Metastasis in Pancreatic Cancer via Degradation of Ferritin Heavy Chain and Mutant p53.
Li J; Lama R; Galster SL; Inigo JR; Wu J; Chandra D; Chemler SR; Wang X
Mol Cancer Ther; 2022 Apr; 21(4):535-545. PubMed ID: 35131878
[TBL] [Abstract][Full Text] [Related]
19. miR-128 Regulates Tumor Cell CD47 Expression and Promotes Anti-tumor Immunity in Pancreatic Cancer.
Xi Q; Chen Y; Yang GZ; Zhang JY; Zhang LJ; Guo XD; Zhao JY; Xue ZY; Li Y; Zhang R
Front Immunol; 2020; 11():890. PubMed ID: 32536914
[TBL] [Abstract][Full Text] [Related]
20. Highlights on the Role of
Hafezi S; Saber-Ayad M; Abdel-Rahman WM
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
